Physician profile
Gary W Easterling
NPI 1134129976
$1,471.65
in general payments reported to CMS, 2019-2025
28 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $103 · 2021: $171 · 2022: $234 · 2023: $318 · 2024: $152 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651 · Education: $34.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.09 |
| Education | $34.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $249.15 | 2022-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $190.75 | 2019-2023 | Liletta |
| Pfizer INC. | $174.30 | 2019-2024 | |
| Hologic Sales and Service, LLC | $166.86 | 2019-2025 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
| Dysis Medical, INC. | $75.91 | 2020 | |
| Amag Pharmaceuticals, INC. | $52.86 | 2019 | |
| Therapeuticsmd, INC. | $39.93 | 2019 | |
| Smith+Nephew, INC. | $34.79 | 2024-2025 | Pico 14 |
| Coopersurgical, INC. | $34.06 | 2022-2023 | Summit Doppler |
| Bayer Healthcare Pharmaceuticals INC. | $32.90 | 2023-2025 | |
| Mylan Pharmaceuticals INC. | $30.59 | 2019-2022 | |
| Ethicon US, LLC | $30.56 | 2022 | |
| Gynesonics, INC. | $28.55 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Avion Pharmaceuticals | $25.31 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $20.42 | 2019 | |
| Avanos Medical | $18.24 | 2019 | |
| Allergan, INC. | $17.04 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.75 | 2019 | |
| Coloplast Corp | $14.25 | 2022 | |
| Exeltis, USA INC. | $13.96 | 2022 | |
| Myovant Sciences INC. | $13.77 | 2022 | |
| Medicem INC. | $13.65 | 2022 | |
| Lupin INC. | $13.35 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.28 | 2019 | |
| Evofem Biosciences, INC. | $13.14 | 2022 | |
| Meditrina | $12.29 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Easterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.